Peer-influenced content. Sources you trust. No registration required. This is HCN.
Medical News Today (MNT)
“The increased risk of NAION with Wegovy is due to the higher dosage of semaglutide…the difference between the two dosages and the rates of NAION may indicate a dose-dependent increase in risk.” – Benjamin Bert, MD
Endocrinology, Diabetes, Metabolism March 24th 2026
British Medical Journal (The BMJ)
“Selecting a GLP-1 receptor agonist over another antihyperglycemic drug could plausibly confer ancillary benefit” in patients at high risk for or living with an SUD. — Study authors
Endocrinology, Diabetes, Metabolism March 18th 2026
“It gives clinicians objective clinical evidence guidance as to the risks and benefits of napping and catching up on sleep during weekends.” — Kaushik Govindaraju, DO, Medical Offices of Manhattan
Endocrinology, Diabetes, Metabolism March 16th 2026
Cardiology Advisor
The Wegovy tablet is the first oral GLP-1 receptor agonist indicated for weight loss and cardiovascular risk reduction in eligible adults.
Endocrinology & Diabetes Nursing March 13th 2026
GoodRx for Healthcare Professionals
If approved, retatrutide will be the first in a new class of medications combining GIP, GLP-1, and glucagon receptor agonism in a single once-weekly injection.
Endocrinology, Diabetes, Metabolism March 13th 2026
Therapeutic Advances in Musculoskeletal Disease
Early treatment phases may transiently promote immune activation, whereas sustained therapy, by reducing BMI and lowering systemic inflammation, may mitigate this effect.
Cardiology March 13th 2026
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS